Clik here to view.
Clik here to view.
BioLegend与Sanquin签署 多肽-MHC检测技术授权协议
圣迭戈 (美国商业资讯) — BioLegend宣布，Sanquin血液制品供应基金会已向其授权了一项研究抗原特异性T细胞的新型技术。位于阿姆斯特丹的Sanquin试剂部门和荷兰癌症研究所 (NKI)...
View ArticleClik here to view.
Osstem Implant Selects Dassault Systèmes’ “License to Cure for Medical...
VELIZY-VILLACOUBLAY, France Dassault Systèmes (Euronext Paris: #13065, DSY.PA) (Paris:DSY), the 3DEXPERIENCE Company, world leader in 3D design software, 3D Digital Mock Up and Product Lifecycle...
View ArticleClik here to view.
サンテック・メディカルの新たなCT40バイタルサインデバイスがMasimo SET®パルスオキシメトリー技術を搭載
スイス・ヌーシャテル & 英アインシャム （ビジネスワイヤ） — マシモ（NASDAQ: MASI）とハルマ（LSE:HLMA）傘下のサンテック・メディカルは本日、Masimo SET®パルスオキシメトリー技術のサンテック製CT40への搭載を共同発表しました。CT40は次世代のスポットチェック用バイタルサインデバイスです。 このSmart News...
View ArticleClik here to view.
BATM’s Adaltis to Receive Investment and Enters into Strategic Joint Venture...
HOD HASHARON, Israel BATM Advanced Communications Limited (LSE: BVC) (“BATM” or “the Group”), a leading provider of real-time technologies for networking solutions and medical laboratory systems, is...
View ArticleClik here to view.
Recent Settlement in Promega/Genovis Case Maintains Continued Offering of...
MADISON, Wis. A recent settlement between Promega Corporation and Genovis AB maintains full freedom for the continued offering of Promega’s IdeS and IdeZ Proteases for markets worldwide. In November...
View ArticleClik here to view.
Poxel Announces Patient Enrollment Completed for Imeglimin Phase 2b Clinical...
LYON, France POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced that it has completed...
View ArticleClik here to view.
Ligand Receives $4 Million from Expansion of Two OmniAb® License Agreements
SAN DIEGO Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that two recent events relating to its OmniAb platform generated $4 million in combined payments due to Ligand. One event...
View ArticleClik here to view.
Takeda to Partner with Altos Therapeutics to Develop Promising Compound for...
OSAKA, Japan & LOS ALTOS, Calif. Takeda Pharmaceutical Company Limited (TSE: 4502) and Altos Therapeutics LLC today jointly announced the companies have entered into a definitive agreement to...
View ArticleClik here to view.
Takeda to Partner with Altos Therapeutics to Develop Promising Compound for...
OSAKA, Japan & LOS ALTOS, Calif. Takeda Pharmaceutical Company Limited (TOKYO:4502) and Altos Therapeutics LLC today jointly announced the companies have entered into a definitive agreement to...
View ArticleClik here to view.
武田薬品とAltos Therapeuticsによる胃不全麻痺治療薬の開発に関する提携について
大阪 & 米カリフォルニア州ロスアルトス （ビジネスワイヤ） — 武田薬品工業株式会社（本社：大阪市中央区、以下「武田薬品」）とAltos Therapeutics...
View ArticleClik here to view.
武田与Altos Therapeutics合作开发有望用于治疗胃轻瘫的化合物
日本大阪和加州洛思阿图斯 (美国商业资讯) — 武田药品工业株式会社(TOKYO:4502)与Altos Therapeutics...
View ArticleClik here to view.
Galderma Announces Approval of Epiduo Gel for the Treatment of Acne in Japan
LAUSANNE, Switzerland Galderma Pharma S.A. (”Galderma” Headquarters: Lausanne, Switzerland, CEO: Stuart Raetzman), a global leader focused on medical solutions in skin health, today announced that...
View ArticleClik here to view.
Celltrion Healthcare announces its commitment to develop anti-drug antibody...
INCHEON, South Korea Celltrion Healthcare, a global biopharmaceutical company, today announced its research commitment to develop laboratory tests that will determine both drug and anti-drug...
View ArticleClik here to view.
Takeda Submits a New Drug Application for Novel, Oral Proteasome Inhibitor...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare in Japan for...
View ArticleClik here to view.
ORALTAG™ (iohexol), a New Oral Contrast Agent for Abdominal CT Scans,...
TOKYO Otsuka Pharmaceutical Co. Ltd. and its wholly-owned subsidiary Interpharma Praha, a.s. announced today that ORALTAG, a formulation of dry, dissolvable iohexol powder for oral solution, will...
View ArticleClik here to view.
Hanmi Selects Medidata to Power Drug Development with Cloud Technology
NEW YORK Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research, announced today that it has signed a multi-year enterprise deal with Hanmi...
View ArticleClik here to view.
スミス・アンド・ネフューのアレビン ライフの使用を取り入れた新プロトコルにより、大施設での院内褥瘡を69%低減
ロンドン （ビジネスワイヤ） — 世界的な医療技術企業のスミス・アンド・ネフュー（LSE:SN）（NYSE:SNN）は、アレビン ライフ（ALLEVYN™ LIFE）の使用を取り入れた総合的な褥瘡対策によって院内褥瘡（HAPU）を顕著に低減できることを示した研究論文の掲載を発表します1。...
View ArticleClik here to view.
Initiation of Phase 1 Clinical Study with Novel Immuno-Oncology Candidate...
TOKYO Sosei Group Corporation (“Sosei”; TOKYO Mothers Index: 4565) today announces Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei Group Corporation, reported that it has...
View ArticleClik here to view.
武田在日本递交新型口服蛋白酶体抑制剂ixazomib的新药申请
日本大阪 (美国商业资讯) –武田药品工业株式会社(TSE: 4502)今天宣布，它已向日本厚生劳动省递交了首个口服蛋白酶体抑制剂ixazomib治疗复发或难治多发性骨髓瘤的新药申请(“NDA”)。...
View Article